<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02026297</url>
  </required_header>
  <id_info>
    <org_study_id>2013P002452</org_study_id>
    <nct_id>NCT02026297</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid and Thromboelastography During Cesarean Delivery</brief_title>
  <acronym>TA TEG</acronym>
  <official_title>The Influence of Prophylactic Tranexamic Acid on Thromboelastography During Cesarean Delivery: A Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to characterize the coagulation changes, using thromboelastography&#xD;
      (TEG), after prophylactic tranexamic administration during cesarean delivery. Specifically,&#xD;
      TEG values will be compared in patients who receive prophylactic tranexamic acid or placebo&#xD;
      before surgery, during elective cesarean delivery, and 2 hours postpartum.&#xD;
&#xD;
      Postpartum hemorrhage (PPH) is increasing in incidence in the United States, renewing&#xD;
      interest in multimodal approaches to blood conservation during cesarean delivery.&#xD;
      Pharmacologic therapy with the antifibrinolytic agent, tranexamic acid (TA), has been shown&#xD;
      to reduce estimated blood loss (EBL) during cesarean delivery, but its effect on global&#xD;
      coagulation as assessed by TEG, and how this correlates with lowering blood loss, has not&#xD;
      been elucidated.&#xD;
&#xD;
      This study will be conducted as a randomized, double-blind, controlled trial with two study&#xD;
      arms: control (60 patients); and treatment (60 patients).&#xD;
&#xD;
      Subjects will be pre-medicated with routine pre-cesarean delivery medications including oral&#xD;
      sodium citrate 30 mL and intravenous (IV) metoclopramide 10 mg. A peripheral IV and&#xD;
      noninvasive hemoglobin monitor will be placed, and baseline labs sent: type and screen, serum&#xD;
      hemoglobin, platelet count, fibrinogen, activated partial thromboplastin time (aPTT),&#xD;
      prothrombin time (PT), and baseline TEG values (r time, k time, alpha angle, and maximum&#xD;
      amplitude). Patients will have blood pressure, heart rate, and pulse oximetry measured&#xD;
      throughout surgery as per standard of care. Patients will all receive IV lactated Ringers'&#xD;
      (LR) solution prior to surgery and throughout surgery, with volume recorded and a goal of&#xD;
      less than 2 L unless more IV fluid is clinically indicated. All patients will have a spinal&#xD;
      anesthetic as per standard of care, with hyperbaric bupivacaine 12 mg, fentanyl 10 μg, and&#xD;
      hydromorphone 100 μg. If the anesthetic plan is altered (combined spinal-epidural, general&#xD;
      anesthesia conversion, general anesthesia planned), indications and medication doses used&#xD;
      will be noted for analysis.&#xD;
&#xD;
      Immediately following induction of anesthesia and prior to skin incision, infusion of study&#xD;
      solution will be initiated.&#xD;
&#xD;
      Study solutions will consist of:&#xD;
&#xD;
        1. Control group: 100 mL 0.9% normal saline (NS).&#xD;
&#xD;
        2. Treatment group: 100 mL 0.9% NS containing 1g tranexamic acid (TA). Study solution will&#xD;
           be infused via an infusion pump over 10 minutes. Blood loss will be measured by visual&#xD;
           estimate and weight of surgical sponges. Noninvasive hemoglobin will be measured&#xD;
           throughout the study. All routine care lab values will be noted. At minimum, one lab&#xD;
           panel will be sent one hour after study solution initiation (hemoglobin, fibrinogen,&#xD;
           platelet count, aPTT, PT, and TEG).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    funding and manpower unavailable, completion within a reasonable timeframe not possible.&#xD;
  </why_stopped>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">February 21, 2020</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TEG Value- Thromboelastography R-time, Control and Treated Groups</measure>
    <time_frame>one hour after initiation of study infusion</time_frame>
    <description>Blood samples will be collected for evaluation one our after initiation of the study infusion. Whole blood samples are tested in a point-of-care thromboelastography machine and R time, or time to initiation of clot formation, is measured in minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraoperative Blood Loss</measure>
    <time_frame>during surgery in the operating room</time_frame>
    <description>Blood loss will be measured using the following methods:&#xD;
visual estimate of blood in the suction canister&#xD;
weight of surgical sponges&#xD;
postoperative hemoglobin values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delayed Complications at the 6-Week Postpartum Visit With the Obstetrician.</measure>
    <time_frame>6 weeks postpartum</time_frame>
    <description>The electronic patient record from each patients' 6-week postpartum visit will be reviewed for the following:&#xD;
delayed bleeding complications, defined as obstetric bleeding requiring surgical intervention, blood transfusion, or both.&#xD;
thrombotic complications including: venous thrombus seen on ultrasound, thromboembolic event</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Control, low risk PPH</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care NOT including tranexamic acid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treated, low risk PPH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care AND tranexamic acid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>1 gram IV over 10 minutes</description>
    <arm_group_label>Treated, low risk PPH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo; Normal Saline</intervention_name>
    <description>0.9% Normal Saline</description>
    <arm_group_label>Control, low risk PPH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) class I or II&#xD;
&#xD;
          -  aged 18-50 years&#xD;
&#xD;
          -  singleton vertex pregnancy&#xD;
&#xD;
          -  scheduled elective cesarean delivery (with or without prior labor) with a planned&#xD;
             pfannenstiel incision&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy to tranexamic acid&#xD;
&#xD;
          -  history of inherited or acquired thrombophilia&#xD;
&#xD;
          -  history of deep vein thrombosis or pulmonary embolism, or use of anticoagulant&#xD;
             medication.&#xD;
&#xD;
          -  preeclampsia, hemolysis, elevated liver enzymes, low platelet syndrome&#xD;
&#xD;
          -  seizure disorder&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 22, 2013</study_first_submitted>
  <study_first_submitted_qc>December 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2014</study_first_posted>
  <results_first_submitted>August 27, 2020</results_first_submitted>
  <results_first_submitted_qc>October 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 27, 2020</results_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Michaela Kristina Farber, MD</investigator_full_name>
    <investigator_title>Instructor of Anesthesia</investigator_title>
  </responsible_party>
  <keyword>postpartum hemorrhage</keyword>
  <keyword>estimated blood loss</keyword>
  <keyword>coagulation</keyword>
  <keyword>thromboelastography</keyword>
  <keyword>tranexamic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control, Low Risk PPH</title>
          <description>Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care NOT including tranexamic acid.&#xD;
Placebo; Normal Saline: 0.9% Normal Saline</description>
        </group>
        <group group_id="P2">
          <title>Treated, Low Risk PPH</title>
          <description>Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care AND tranexamic acid.&#xD;
Tranexamic Acid: 1 gram IV over 10 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients scheduled for elective cesarean delivery with low risk for postpartum hemorrhage.</population>
      <group_list>
        <group group_id="B1">
          <title>Control, Low Risk PPH</title>
          <description>Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care NOT including tranexamic acid.&#xD;
Placebo; Normal Saline: 0.9% Normal Saline</description>
        </group>
        <group group_id="B2">
          <title>Treated, Low Risk PPH</title>
          <description>Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care AND tranexamic acid.&#xD;
Tranexamic Acid: 1 gram IV over 10 minutes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.2" lower_limit="30" upper_limit="40"/>
                    <measurement group_id="B2" value="31.9" lower_limit="20" upper_limit="39"/>
                    <measurement group_id="B3" value="32.9" lower_limit="20" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>TEG Value- Thromboelastography R-time, Control and Treated Groups</title>
        <description>Blood samples will be collected for evaluation one our after initiation of the study infusion. Whole blood samples are tested in a point-of-care thromboelastography machine and R time, or time to initiation of clot formation, is measured in minutes.</description>
        <time_frame>one hour after initiation of study infusion</time_frame>
        <population>Thromboelastography R-time</population>
        <group_list>
          <group group_id="O1">
            <title>Control, Low Risk PPH</title>
            <description>Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care NOT including tranexamic acid.&#xD;
Placebo; Normal Saline: 0.9% Normal Saline</description>
          </group>
          <group group_id="O2">
            <title>Treated, Low Risk PPH</title>
            <description>Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care AND tranexamic acid.&#xD;
Tranexamic Acid: 1 gram IV over 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>TEG Value- Thromboelastography R-time, Control and Treated Groups</title>
          <description>Blood samples will be collected for evaluation one our after initiation of the study infusion. Whole blood samples are tested in a point-of-care thromboelastography machine and R time, or time to initiation of clot formation, is measured in minutes.</description>
          <population>Thromboelastography R-time</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="4.2" upper_limit="7.7"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.4" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intraoperative Blood Loss</title>
        <description>Blood loss will be measured using the following methods:&#xD;
visual estimate of blood in the suction canister&#xD;
weight of surgical sponges&#xD;
postoperative hemoglobin values</description>
        <time_frame>during surgery in the operating room</time_frame>
        <population>weight of surgical sponges</population>
        <group_list>
          <group group_id="O1">
            <title>Control, Low Risk PPH</title>
            <description>Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care NOT including tranexamic acid.&#xD;
Placebo; Normal Saline: 0.9% Normal Saline</description>
          </group>
          <group group_id="O2">
            <title>Treated, Low Risk PPH</title>
            <description>Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care AND tranexamic acid.&#xD;
Tranexamic Acid: 1 gram IV over 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Blood Loss</title>
          <description>Blood loss will be measured using the following methods:&#xD;
visual estimate of blood in the suction canister&#xD;
weight of surgical sponges&#xD;
postoperative hemoglobin values</description>
          <population>weight of surgical sponges</population>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="637" spread="151"/>
                    <measurement group_id="O2" value="685" spread="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Delayed Complications at the 6-Week Postpartum Visit With the Obstetrician.</title>
        <description>The electronic patient record from each patients' 6-week postpartum visit will be reviewed for the following:&#xD;
delayed bleeding complications, defined as obstetric bleeding requiring surgical intervention, blood transfusion, or both.&#xD;
thrombotic complications including: venous thrombus seen on ultrasound, thromboembolic event</description>
        <time_frame>6 weeks postpartum</time_frame>
        <population>postpartum Obstetrician evaluation at 6 weeks: obstetric bleeding requiring surgical intervention, blood transfusion, or both; thrombotic complications including: venous thrombus seen on ultrasound, thromboembolic event</population>
        <group_list>
          <group group_id="O1">
            <title>Control, Low Risk PPH</title>
            <description>Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care NOT including tranexamic acid.&#xD;
Placebo; Normal Saline: 0.9% Normal Saline</description>
          </group>
          <group group_id="O2">
            <title>Treated, Low Risk PPH</title>
            <description>Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care AND tranexamic acid.&#xD;
Tranexamic Acid: 1 gram IV over 10 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Delayed Complications at the 6-Week Postpartum Visit With the Obstetrician.</title>
          <description>The electronic patient record from each patients' 6-week postpartum visit will be reviewed for the following:&#xD;
delayed bleeding complications, defined as obstetric bleeding requiring surgical intervention, blood transfusion, or both.&#xD;
thrombotic complications including: venous thrombus seen on ultrasound, thromboembolic event</description>
          <population>postpartum Obstetrician evaluation at 6 weeks: obstetric bleeding requiring surgical intervention, blood transfusion, or both; thrombotic complications including: venous thrombus seen on ultrasound, thromboembolic event</population>
          <units>complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All patients enrolled in this study were evaluated in the immediate treatment period through the time of discharge (average duration 4 days) and then records were reviewed from the 6-week postpartum followup for delayed complications.</time_frame>
      <desc>obstetric bleeding requiring surgical intervention, blood transfusion, or both.&#xD;
thrombotic complications including: venous thrombus seen on ultrasound, thromboembolic event</desc>
      <group_list>
        <group group_id="E1">
          <title>Control, Low Risk PPH</title>
          <description>Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care NOT including tranexamic acid.&#xD;
Placebo; Normal Saline: 0.9% Normal Saline</description>
        </group>
        <group group_id="E2">
          <title>Treated, Low Risk PPH</title>
          <description>Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care AND tranexamic acid.&#xD;
Tranexamic Acid: 1 gram IV over 10 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michaela K. Farber</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>6177591609</phone>
      <email>mfarber@bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

